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INTRODUCTION
Children with Down syndrome are predisposed to devel-
oping acute leukemia. The most common leukemia associ-
ated with Down syndrome is acute megakaryoblastic leu-
kemia (AMKL), and the incidence is approximately 500-
fold higher than in healthy children (1). Transient myelo-
proliferative disorder (TMD) is a leukemoid reaction occur-
ring occasionally in Down syndrome newborn infants, and
is characterized by the rapid growth of abnormal blast cells
expressing megakaryocytic markers. Although most TMD
cases resolve spontaneously, AMKL develops in approximate-
ly 20% to 30% of TMD cases in the first 4 yr of life, often
preceded by a myelodysplastic phase. Recently, acquired
mutations in the N-terminal activation domain of the GATA1
gene, encoding a zinc-finger transcription factor that regu-
lates the normal development of the megakaryocytic, ery-
throid, basophilic/mast cell and eosinophilic lineages, have
been reported in TMD and Down syndrome-related AMKL
(DS-AMKL) (2). Two isoforms of GATA-1 protein are usu-
ally detected: a full-length GATA-1 translated from the first
start codon ATG on exon 2, and a 40-kDa shorter form,
GATA-1s that initiated from an ATG on exon 3. Most of
the mutations in TMD and DS-AMKL were located in the
regions including exon 2 and an identical mutation in spec-
imens from TDM and AMKL have been found in Down
syndrome patients (3-8). The mutation results in the intro-
duction of a premature stop codon in the gene sequence that
encodes the N-terminal activation domain, and a lack of
expression of the full-length GATA-1.
Here we describe a 3-yr-old girl patient with DS-AMKL,
who was found to have a novel GATA1 gene mutation and
complex cytogenetic aberrations including constitutional
trisomy 21, clonal monosomy 7, and an additional copy of
chromosome 21. To the best of our knowledge, this is a first
case of DS-AMKL with a GATA1 gene mutation described
in Korea. This case indicate that expression of an abnormal
GATA-1s with a defective N-terminal activation domain, in
the absence of full-length GATA-1, and that other genetic
changes contribute to the development of DS-AMKL, pre-
viously described in Caucasians and now in a Korean patient.
CASE REPORT
A 3-yr-girl patient with Down syndrome was admitted
because of pallor and fever. Initial laboratory tests showed
Hb 2.7 g/dL, WBC 9.77×109/L, and platelets 7×109/L.
A peripheral blood smear revealed that 52% of the white
blood cells were blasts with a round nucleus with fine retic-
ular chromatin, one to three nucleoli and cytoplasmic bleb,
and the bone marrow aspirate smear revealed that the blasts
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A Novel Mutation in the GATA1 Gene Associated with Acute
Megakaryoblastic Leukemia in a Korean Down Syndrome Patient
Although acquired mutations in the GATA1 gene have been reported for Down
syndrome-related acute megakaryoblastic leukemia (DS-AMKL) in Caucasians,
this is the first report of a Korean Down syndrome patient with AMKL carrying a
novel mutation of the GATA1 gene. A 3-yr-old Korean girl with Down syndrome
was admitted to our hospital complaining of pallor and fever. The findings of a periph-
eral blood smear and bone marrow study were compatible with the presence of
AMKL. A chromosome study showed 48,XX,-7,+21c,+21,+r[3]/47,XX,+21c[17].
Following GATA1 gene mutation analysis, a novel mutation, c.145dupG (p.Ala49Glyf-
sX18), was identified in the N-terminal activation domain of the GATA1 gene. This
mutation caused a premature termination at codon 67 and expression of an abnor-
mal GATA-1 protein with a defective N-terminal activation domain, and the absence
of full-length GATA-1 protein. This case demonstrates that a leukemogenic mech-
anism for DS-AMKL is contributed by a unique collaboration between overexpressed
genes from trisomy 21 and an acquired GATA1 mutation previously seen in Cau-
casians and now in a Korean patient.
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Accepted : 28 December 2007were counted at 73% (Fig. 1A). Flow cytometric analyses
showed that these blasts were CD13+, CD33+, CD34+,
HLA-DR+, CD61+, and aberrant CD7+. A cytochemical
stain showed reactivity with CD61 and punctuate nonspecif-
ic esterase reactivity and negativity for sudan black B and
peroxidase; the blasts were compatible with the features of
megakaryoblasts (Fig. 1B). Cytogenetic analysis of the bone
marrow cells revealed 48,XX,-7,+21c,+21,+r[3]/47,XX,
+21c[17] (Fig. 2A). We analyzed the GATA1 mutation in
this patient after obtaining informed consent from the par-
ents. The genomic DNA was isolated from the bone marrow
leukocytes using a Wizard genomic DNA purification kit
following the manufacturer’s instruction (Promega, Madi-
son, WI, U.S.A.). The GATA1 gene was amplified by use of
the polymerase chain reaction (PCR) with use of the appro-
priate primers (available upon request) and a thermal cycler
(Model 9700, Applied Biosystems, Foster City, CA, U.S.A.).
Direct DNA sequencing was performed with the BigDye
Terminator Cycle Sequencing Ready Reaction kit (Applied
Biosystems) on an ABI Prism 3100 genetic analyzer (Applied
Biosystems). Following GATA1 gene mutation analysis, a
novel mutation, c.145dupG (p.Ala49GlyfsX18), was iden-
tified in the N-terminal activation domain, exon 2 of GATA1
(Fig. 3). This mutation resulted in a premature stop codon
at amino acid 67 and resulted in the production of GATA-1s.
The parents of the patient denied a history of TMD. A final
diagnosis was confirmed as DS-AMKL. The patient received
intensified induction chemotherapy (daunorubicin 45 mg/m2
with cardioxane, cytosine arabinoside 100 mg/m2, and int-
rathecal cytosine arabinoside 30 mg) and achieved complete
remission on day 28. The follow-up studies on day 28 revealed
cytogenetic and morphological remission. The leukemia
relapsed under the course of the consolidation chemothera-
py, 11 months later. The blasts reappeared on a peripheral
blood smear and bone marrow aspirate smear, and repre-
sented up to 34% of the white blood cells and 49% of all of
the nucleated cells, respectively. Flow cytometric analyses
showed the same results as the initial leukemic clone. Cyto-
genetic analysis with bone marrow cells revealed only con-
stitutional trisomy 21 (47,XX,+21c[20]) (Fig. 2B). Although
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Fig. 1. Bone marrow aspiration revealed that blasts were 73% (A) and cytochemical stain showed reactivity with CD61 and punctuate
nonspecific esterase reactivity (B), and negativity on peroxidase and sudan black B.
A B
Fig. 2. Cytogenetic analysis of bone marrow cells revealed 48,XX,7,+21c,+21,+r[3]/47,XX,+21c[17] at initial diagnosis (A) and only con-
stitutional trisomy 21 at relapse (B).
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11the peak of the mutated GATA1 gene sequence of the speci-
men taken after relapse was lower than that of the initial spec-
imen, the same mutation was detected after relapse.
DISCUSSION
Recently, acquired mutations in the GATA1 gene that
have been reported in nearly all cases of TMD and DS-AMKL
have been shown to be specific for DS-AMKL (3, 7). GATA1
mutations are present in blasts of TMD and show the iden-
tical GATA1 mutation in sequential samples collected from
a patient during TMD, and subsequently AMKL. These
findings suggest a model of malignant transformation in
DS-AMKL in which GATA1 mutations are an early event
and AMKL arises from latent TMD clones following initial
apparent remission (9). The mutation expresses only a trun-
cated mutant of the GATA1 gene and a short form of the
protein, GATA-1s, is produced. Full-length GATA-1 induces
differentiation toward the erythroid/megakaryoblastic lin-
eage. However, expression of GATA-1s did not induce ery-
throid/megakaryoblastic differentiation. These results indi-
cate that expression of only GATA-1s with a defective N-
terminal activation domain contributes to the expansion of
TMD blast cells, and that other genetic changes contribute
to the development of AMKL in Down syndrome (7, 9).
Down syndrome of this patient was recognized by the
physician at admission. This patient had no known clinical
history of TMD. The GATA1 mutation may be present at
birth in many cases in patients without known clinical TMD,
and who later develop AMKL (6). Unfortunately, we did
not confirm the presence of the same GATA1 mutation at
birth in this case. After relapse, the same GATA1 mutation
was detected. 
Studies on TMD or AMKL in Down syndrome are espe-
cially lacking for Korean patients.
The detection of GATA1 mutation is highly suggestive
of DS-AMKL, and is important in the understanding Down
syndrome-related leukemogenesis, and a new target for the
detection of minimal residual disease (10). For children with
no obvious symptoms of Down syndrome, detection of a
GATA1 mutation is highly informative to distinguish bet-
ween DS-AMKL and a non-Down syndrome AMKL. How-
ever, GATA1 mutations are not associated with every case of
DS-AMKL. This may be due to a technical limitation in
detecting a GATA1 mutation in a sample with a low blast
population, or alternatively, an indication that a separate class
of DS-AMKL exists. While GATA1 mutations have been
detected in children diagnosed with DS-AMKL as old as 50
months, very few cases of children older than 4 yr have been
studied to be significant (8). Children older than 4 yr and
with the absence of a GATA1 mutation in DS-AMKL face
the worst prognosis. Further studies into the potential use
of GATA1 mutation analysis for the diagnosis of DS-AMKL
are therefore needed.
GATA1 mutations have been found in otherwise healthy
Down syndrome neonates at birth, that have not yet devel-
oped TMD or AMKL (6). These findings suggest that acq-
uired mutations in GATA1 and the generation of GATA-1s
cooperate frequently with trisomy 21 in initiating megakary-
oblastic proliferation, but are insufficient for the progression
to AMKL. Mutagenesis of GATA1 is an initiating event in
Down syndrome-associated leukemogenesis. GATA1 muta-
tions have not been found in non-Down syndrome patients
with leukemia of any kind, with the following exception.
Children without Down syndrome, but with acquired trisomy
21, trisomy 21 mosaicism, or tertasomy 21 in their leukemic
cells, may, on rare occasions, present with AMKL that har-
bors a GATA1 mutation (11). Therefore, increased expres-
sion of certain chromosome 21 genes in the same cell that
carries the GATA1 mutation may enhance its proliferation
and survival (12). There are several genes on the small chro-
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Fig. 3. Direct DNA sequencing analyses
of the GATA1 gene revealed a novel
mutation, c.145dupG (p.Ala49GlyfsX18),
identified in the N-terminal activation
domain of exon 2 of GATA1. This muta-
tion produced a premature stop codon
at amino acid 67 and expression of an
abnormal short variant, GATA-1s, with
a defective N-terminal activation do-
main, in the absence of the full-length
GATA-1. The same mutation was dis-
covered in a specimen taken following
relapse.mosome 21 that encode proteins that may enhance megakary-
opoiesis. These genes include RUNX1/AML1 (13, 14), ERG
(15), Ets2, and a newly discovered group of genes coding for
regulatory micro-RNAs (12, 16). ERG is an Ets transcrip-
tion factor and excess expression of ERG in hematopoietic
progenitor cells, coupled with a differentiation arrest is caused
by the acquisition of mutations in GATA1 (15). Overexpres-
sion of ERG, perhaps in conjunction with other factors such
as Ets2, may contribute to expanded megakaryopoiesis cells
harboring trisomy 21. RUNX1/AML1 is known to be the
most frequent target for a chromosomal translocation in
leukemia. Recently, point mutations in the Runt domain of
the AML1 gene have also been reported in cells from leu-
kemia patients (17). Interestingly, AML1 mutations are fre-
quently found in myeloid malignancies with acquired 21
trisomy (18). It has been suggested that increased RUNX1
activity has a role in DS-AMKL development due to the
physical interaction and synergy between GATA1 and RUNX1
(13). To understand further the mechanisms of a lineage-spe-
cific malignant conversion, it is very important to identify
the gene or genes on chromosome 21 that cooperate with
mutated GATA1 as well as additional genetic changes in
TMD blast cells during the development of DS-AMKL. There-
fore, the development of DS-AMKL requires at least three
cooperating events-trisomy 21, a GATA1 mutation, and a
third, as yet undefined, additional genetic alteration (16).
Although acquired mutations in the GATA1 gene have
been reported in DS-AMKL in Caucasians, this is a first case
of a Korean Down syndrome patient with AMKL carrying
a novel mutation of GATA1 gene. This case demonstrates
that expression of the abnormal GATA-1s with a defective
N-terminal activation domain, in the absence of full-length
GATA-1, contributes to the development of DS-AMKL, as
seen previously in Caucasians and now in a Korean patient.
Large and prospective studies are needed to reveal GATA1
mutations and additional genetic alternations, such as over-
expression of RUNX1/AML1 or EGR, for the development
of DS-AMKL in Down syndrome patients.
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